XSDR:LSE:LSE-Xtrackers MSCI Europe Health Care ESG Screened UCITS ETF 1C (GBX)

ETF | Others |

Last Closing

USD 17879

Change

-71.00 (-0.40)%

Market Cap

USD 0.23B

Volume

741.00

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2025-04-03 )

Largest Industry Peers for Others

Symbol Name Price(Change) Market Cap
0R1O:LSE Amazon.com Inc.

-6.05 (-3.40%)

USD 1,607.29B
LCJP:LSE Lyxor Core MSCI Japan (DR) UCI..

-0.42 (-3.18%)

USD 640.06B
LCJD:LSE Amundi MSCI Japan (DR) UCITS E..

-0.55 (-3.27%)

USD 640.06B
0R1I:LSE NVIDIA Corp.

-2.74 (-2.68%)

USD 618.20B
0R1G:LSE Home Depot Inc.

N/A

USD 373.16B
0QZK:LSE Coca-Cola Co.

-2.60 (-3.69%)

USD 266.08B
PRJU:LSE Amundi Index Solutions - Amund..

-0.78 (-2.78%)

USD 259.48B
0QZO:LSE 0QZO

-2.30 (-2.72%)

USD 258.54B
0QZ3:LSE Qualcomm Inc.

-9.50 (-7.07%)

USD 202.26B
0R24:LSE Intel Corp.

-0.59 (-3.00%)

USD 196.14B

ETFs Containing XSDR:LSE

N/A

Market Performance

  Market Performance vs. Industry/Classification (Others) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -0.02% 56% F 58% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -0.02% 55% F 57% F
Trailing 12 Months  
Capital Gain -5.70% 21% F 36% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -5.70% 20% F 35% F
Trailing 5 Years  
Capital Gain 36.25% 40% F 50% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 36.25% 36% F 47% F
Average Annual (5 Year Horizon)  
Capital Gain 8.20% 57% F 62% D
Dividend Return 8.20% 56% F 61% D-
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 6.43% 82% B 91% A-
Risk Adjusted Return 127.47% 97% N/A 98% N/A
Market Capitalization 0.23B 61% D- 35% F

Annual Financials (GBX)

Quarterly Financials (GBX)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

Low volatility

The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.

What to not like:

There is nothing we particularly dislike